Kusapin

Oxcarbazepine

Mono- or adjunctive therapy for partial seizures w/ or w/o secondary generalized tonic-clonic seizures.

Adult Initially 600 mg/day (8-10 mg/kg/day) given in 2 divided doses. Maintenance dose: 600 mg/day increments at approx wkly intervals from starting dose. Max: 2,400 mg/day. Childn ≥6 yr 8-10 mg/kg/day in 2 divided doses. Maintenance dose: 30-46 mg/kg/day. May be increased by 10 mg/kg/day at approx wkly intervals from starting dose. Max: 46 mg/kg/day. Renal impairment CrCl <30 mL/min Initially, 300 mg/day & increased at wkly intervals. Elderly Adjust dose if w/ compromise renal function.

May be taken with or without food: For patients w/ difficulty swallowing, tab may be broken into two halves.

Hypersensitivity.

Discontinue use & start alternative treatment if class I hypersensitivity occurs. Serious dermatological reactions may occur including Stevens-Johnson syndrome, toxic epidermal necrolysis (Lyell's syndrome) & erythema multiforme; measure serum Na levels prior to therapy in patients w/ preexisting renal conditions associated w/ low Na or those concomitantly treated w/ Na-lowering drugs. Regularly weigh patients w/ cardiac insufficiency & secondary heart failure to determine occurrence of fluid retention. Hepatitis may occur; elevate liver function & consider discontinuation when hepatic event is suspected. Agranulocytosis, aplastic anemia may occur; discontinue use if significant bone marrow depression develops. May increase risk of suicidal behavior. May render contraceptives ineffective. Possible additive sedative effect w/ alcohol. May impair ability to drive & use machines. Do not interrupt therapy during pregnancy; folic acid supplementation is recommended due to possible therapy-associated folic acid deficiency; administer vit K in the last wks of pregnancy & to the newborn as preventive measure to possible bleeding disorders in the newborn. Do not use during lactation.

Somnolence, headache, dizziness; diplopia; nausea, vomiting; fatigue. Hyponatremia; confusional state, depression, apathy, agitation (eg, nervousness), affect lability; ataxia, tremor, nystagmus, disturbance in attention, amnesia; blurred vision, visual disturbance; vertigo; diarrhea, constipation, abdominal pain; rash, alopecia, acne; asthenia.

Lowered plasma conc of immunosuppressants (eg, ciclosporin, tacrolimus), OC, & some other antiepileptics (eg, carbamazepine). May render ethinylestradiol & levonorgestrel ineffective. Increased phenytoin plasma levels upto 40% w/ oxcarbamazepine closes >1,200 mg/day. May lower lamotrigine conc, & increase risk of adverse events (nausea, somnolence, dizziness & headache). May enhance neurotoxicity in concomitant use w/ lithium.

Anticonvulsants

N03AF02 - oxcarbazepine ; Belongs to the class of carboxamide derivatives antiepileptic.

POM